EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids

Fan Zhang, Yuxiang Wang, Xi Zhang, Yuting Bai, Li Zhang, Shuqing Wei

Frontiers in Oncology · 12.05.2026 · 16

DOI: 10.3389/fonc.2026.1742943 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 12.05.2026. Verfasst von Fan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comprehensive Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Scien…. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer deaths worldwide. Despite substantial therapeutic advances, the prognosis of lung cancer patients remains dismal. Here, we report a case of advanced lung adenocarcinoma harboring EGFR exon 21 L858R mutations who finally achieved partial response (PR) in the lung lesion following patient-derived tumor organoid (PDTO)-guided personalized therapy, even after multiple lines of systemic treatment. In May 2021, a 52-year-old woman was diagnosed with right lung adenocarcinoma (cT3N2M1c IVB), accompanied by multiple metastases. Although Osimertinib was initiated as first-line therapy based on the identified EGFR exon 21 L858R mutations, the patient experienced disease progression. Subsequent treatment with ivonescimab plus pemetrexed disodium was administered, but disease progression persisted. Based on serial organoid drug sensitivity testing, repeated adjustments to the therapeutic regimen were made, and the patient ultimately achieved PR in the lung lesion. Our case demonstrates that the lung cancer organoids serve as a powerful preclinical platform for individualized treatment selection in patients with advanced lung adenocarcinoma via rapid functional drug screening. This personalized strategy shows great potential to optimize clinical outcomes for heavily pretreated patients.

Schlagwörter

Stichwörter der Autor:innen

EGFR mutationsadvanced lung adenocarcinomapatient-derived tumor organoidspersonalized treatmentsacituzumab govitecan

Autor:innen und Institutionen

  • Department of Comprehensive Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan,…
  • Ultrasonic Department, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.

Zitieren

APA

Zhang, F., Wang, Y., Zhang, X., Bai, Y., Zhang, L., & Wei, S. (2026). Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1742943

Vancouver

Zhang F, Wang Y, Zhang X, Bai Y, Zhang L, Wei S. Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1742943

BibTeX
@article{Zhang2026,
  author = {Zhang, Fan and Wang, Yuxiang and Zhang, Xi and Bai, Yuting and Zhang, Li and Wei, Shuqing},
  title = {Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1742943}
}
Kostenlos starten →